派安普利单抗(Penpulimab) - 药物靶点：PD-1_在研适应症：鼻咽癌，鳞状非小细胞肺癌，典型霍奇金淋巴瘤_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

安尼可

靶点

PD-1

作用方式

抑制剂

作用机制

PD-1抑制剂(细胞程序性死亡-1抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [8]

在研适应症

鼻咽癌鳞状非小细胞肺癌典型霍奇金淋巴瘤+ [24]

非在研适应症

进展期胃腺癌分化型甲状腺癌食管鳞状细胞癌+ [12]

原研机构

中山康方生物医药有限公司

在研机构

中山康方生物医药有限公司

正大天晴药业集团股份有限公司正大天晴康方(上海)生物医药科技有限公司

+ [2]

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (2021-08-03),

典型霍奇金淋巴瘤

最高研发阶段(中国)批准上市

特殊审评附条件批准 (中国)、快速通道 (美国)、突破性疗法 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

Sequence Code 616719118L

来源: *****

Sequence Code 616722917H

来源: *****

关联

116

项与派安普利单抗相关的临床试验

NCT06825494

/ Not yet recruiting临床1/2期

An Open-label Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab + Chemotherapy in Patients With Advanced Solid Tumors - Cohort A

This trial is part of a multicenter, open-label Phase Ib/II clinical study evaluating the efficacy, safety, and tolerability of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors. Phase Ib of Cohort A1 determines the dose of LM-108 in combination with penpulimab + oxaliplatin + capecitabine. Phase II explores the efficacy and safety of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors.

开始日期2025-03-01

申办/合作机构

正大天晴药业集团股份有限公司

NCT06821503

/ Not yet recruiting临床1/2期

An Open Label Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab Plus Chemotherapy in Patients With Advanced Solid Tumors - Cohort C

This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid tumors. The dose of LM-108 combined with penpulimab, albumin paclitaxel, and gemcitabine is recommended in Phase Ib.Explore the efficacy and safety of LM-108 combined with anti-tumor therapy in patients with advanced pancreatic cancer in Phase II.

开始日期2025-02-01

申办/合作机构

正大天晴药业集团股份有限公司

CTR20243929

/ Recruiting临床2期

评价注射用TQB2102联合免疫±化疗在不可切除的局部晚期、复发性或转移性HER2阳性胃食管腺癌患者中有效性和安全性的Ⅱ期临床试验

主要目的：评价注射用TQB2102联合贝莫苏拜单抗/派安普利单抗±化疗在不可切除的局部晚期、复发性或转移性HER2阳性胃食管腺癌中的有效性。次要目的：评价注射用TQB2102联合贝莫苏拜单抗/派安普利单抗±化疗在不可切除的局部晚期、复发性或转移性HER2阳性胃食管腺癌中的安全性；探索性目的：评价注射用TQB2102在不可切除的局部晚期、复发性或转移性HER2阳性胃食管腺癌的药代动力学（PK）特征和免疫原性；与疗效、作用机制、安全性和/或病理机制相关的生物标志物研究。

开始日期2024-11-14

申办/合作机构

正大天晴药业集团南京顺欣制药有限公司

100 项与派安普利单抗相关的临床结果

登录后查看更多信息

100 项与派安普利单抗相关的转化医学

登录后查看更多信息

100 项与派安普利单抗相关的专利（医药）

登录后查看更多信息

60

项与派安普利单抗相关的文献（医药）

2024-12-01·The Clinical Respiratory Journal

Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature

Review

作者: Zhao, Kelei ; Liu, Yanting ; Zhang, Jinghang ; Zhang, Jingjing ; Yuan, Xiaohan ; Wang, Yuanhang ; Zhang, Min ; Lu, Ping

ABSTRACTSMARCA4‐deficient undifferentiated tumor (SMARCA4‐UT) in the chest is a high‐grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, we report a case of SMARCA4‐UT in a patient who showed a swift response to a combination treatment of penpulimab, anlotinib, and chemotherapy. A 55‐year‐old man was diagnosed with thoracic SMARCA4‐UT along with metastases to multiple lymph nodes, the pleura, and bones. Immunohistochemical (IHC) testing indicated the absence of PD‐L1 expression in tumor cells. He was given sintilimab and anlotinib as first line treatment. However, a follow‐up chest CT revealed progressive disease (PD) after the first cycle treatment. Subsequently, the second line regimen was modified to etoposide and cisplatin (EP) combined with anlotinib and penpulimab. The effectiveness evaluation revealed partial remission (PR) following two cycles of the second‐line regimen treatment. Notably, the patient's progress‐free survival (PFS) exceeds 7 months and the overall survival up to 12 months. Our case implies that a combination of chemotherapy, anlotinib, and penpulimab might offer a promising therapeutic approach for PD‐L1‐negative thoracic SMARCA4‐UT.

2024-10-01·Cancer Pathogenesis and Therapy

Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial

Article

作者: Shi, Yuankai ; Wu, Kailiang ; Sun, Yan ; Wang, Rui ; Liu, Qiang ; Zhang, Changgong ; Wang, Jun ; Wu, Huijuan ; Zhao, Jun ; Mu, Xinlin ; Gao, Liying ; Bai, Chunmei ; Jia, Zhongyao ; Chen, Jianhua

BackgroundCurrently, the need for new therapeutic strategies involving programmed cell death protein-1 (PD-1) monoclonal antibodies in the second-line setting of small cell lung cancer (SCLC) is urgent. This study aimed to evaluate the efficacy and safety of anlotinib plus penpulimab as a second-line treatment for patients with SCLC who progressed after first-line platinum-based chemotherapy.MethodsThis study included the patients from Cohort 4 of a single-arm, open-label, multicenter, phase II clinical trial. A safety run-in phase was performed under anlotinib (10/12 mg quaque die [QD], days 1-14) plus penpulimab (200 mg intravenously [IV], day 1) in a 21-day cycle, followed by the formal trial in which the patients received anlotinib (12 mg QD, days 1-14) plus penpulimab (200 mg IV, day 1) in a 21-day cycle. The primary endpoint of the safety run-in phase was safety. The primary endpoint of the formal trial phase was the objective response rate (ORR).ResultsFrom April 28, 2020, to November 24, 2020, 21 patients were enrolled from 11 hospitals, including 2 in the safety run-in phase and 19 in the formal trial phase. In the formal trial phase, the ORR was 42.1% (8/19; 95% confidence interval [CI]: 17.7-66.6%). The median progression-free survival was 4.8 months (95% CI: 2.9-11.3 months), and the median overall survival was 13.0 months (95% CI: 4.6-not applicable [NA] months). The incidence of ≥grade 3 treatment-related adverse events (TRAEs) was 52.4% (11/21), and the incidence of treatment-related serious adverse events (AEs) was 28.6% (6/21). Two AE-related deaths occurred. The most common AEs were hypertension (57.1%, 12/21), hypothyroidism (42.9%, 9/21), and hypertriglyceridemia (38.1%, 8/21).ConclusionsIn patients with SCLC who progressed after first-line platinum-based chemotherapy, the second-line anlotinib plus penpulimab treatment demonstrates promising anti-cancer activity and a manageable safety profile, which warrants further investigation.Trial registrationNo. NCT04203719, https://clinicaltrials.gov/.

2024-06-30·Annals of Coloproctology

Venous thromboembolism among Asian populations with localized colorectal cancer undergoing curative resection: is pharmacological thromboprophylaxis required? A systematic review and meta-analysis

Review

作者: Tan, Emile Kwong-Wei ; Sultana, Rehena ; Seow-En, Isaac ; Tan, Shih Jia Janice ; Ng, Yvonne Ying Ru ; Allen, John Carson ; Chok, Aik Yong ; Mathew, Ronnie

Purpose: We compared the incidence of venous thromboembolism (VTE) among Asian populations with localized colorectal cancer undergoing curative resection with and without the use of pharmacological thromboprophylaxis (PTP).Methods: A comprehensive literature search was undertaken to identify relevant studies published from January 1, 1980 to February 28, 2022. The inclusion criteria were patients who underwent primary tumor resection for localized nonmetastatic colorectal cancer; an Asian population or studies conducted in an Asian country; randomized controlled trials, case-control studies, or cohort studies; and the incidence of symptomatic VTE, deep vein thrombosis, and/or pulmonary embolism as the primary study outcomes. Data were pooled using a random-effects model. This study was registered in PROSPERO on October 11, 2020 (No. CRD42020206793).Results: Seven studies (2 randomized controlled trials and 5 observational cohort studies) were included, encompassing 5,302 patients. The overall incidence of VTE was 1.4%. The use of PTP did not significantly reduce overall VTE incidence: 1.1% (95% confidence interval [CI], 0%–3.1%) versus 1.9% (95% CI, 0.3%–4.4%; P = 0.55). Similarly, PTP was not associated with significantly lower rates of symptomatic VTE, proximal deep vein thrombosis, or pulmonary embolism.Conclusion: The benefit of PTP in reducing VTE incidence among Asian patients undergoing curative resection for localized colorectal cancer has not been clearly established. The decision to administer PTP should be evaluated on a case-bycase basis and with consideration of associated bleeding risks.

282

项与派安普利单抗相关的新闻（医药）

2025-03-17

·PRNewswire

Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

HONG KONG, March 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy. Previously, penpulimab was approved for use as a third-line treatment for advanced NPC. With this new approval, penpulimab now provides comprehensive treatment coverage across all stages of NPC, offering patients a continuous immunotherapy option from first-line to third-line therapy. This marks the fourth approved indication for penpulimab. In addition to the two NPC indications, penpulimab is also approved for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) when combined with chemotherapy, as well as for monotherapy in patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have previously received at least two lines of systemic chemotherapy. Furthermore, a supplemental New Drug Application (sNDA) for penpulimab in combination with anlotinib for first-line treatment of advanced hepatocellular carcinoma (HCC) is currently under review. Professor Hu Chaosu, one of the principal investigators of penpulimab at Fudan University Shanghai Cancer Center, said: "In China, there remains a significant unmet clinical need for NPC. As the only IgG1 subtype anti-PD-1 monoclonal antibody globally, penpulimab has demonstrated robust efficacy in clinical studies, enhancing the effectiveness of immunotherapy for NPC. The approval for first-line treatment marks a major milestone, as it provides a comprehensive treatment regimen for clinicians and patients, benefiting a large population of NPC patients in China, from first-line to third-line therapy." Professor Chen Xiaozhong, one of the principal investigators of penpulimab at Zhejiang Cancer Hospital, said: "Nasopharyngeal cancer (NPC) is a highly prevalent malignancy in certain regions, and patients with recurrent or metastatic NPC typically face a poor prognosis. Penpulimab has demonstrated a significantly high response rate and prolonged survival benefits in both first-line treatment of NPC and in patients with metastatic NPC who have failed multiple lines of prior therapy. Additionally, it has shown a favorable safety profile, with a low incidence of immune-related adverse events. " Dr. Xia Yu, Founder, Chairwoman, CEO, and President of Akeso, said: "We want to extend our sincere gratitude to all the researchers, clinical trial participants, and NPC patients who have contributed to this milestone. With its differentiated design, penpulimab has gained widespread recognition among clinicians and patients for its efficacy and safety in treating diseases like non-small cell lung cancer (NSCLC), Hodgkin lymphoma, and nasopharyngeal cancer. The approval for first-line treatment of advanced NPC will allow more patients in China to benefit from this new PD-1 monoclonal antibody, further improving survival outcomes." "As key drugs like cadonilimab, ivonescimab, and penpulimab receive approval for a wide range of indications, Akeso's commitment to innovation and excellence in drug development—from discovery to clinical application—is clearly demonstrated. These advancements are not only improving patient outcomes but also reaffirming our dedication to transforming global healthcare. Moving forward, Akeso will continue to pioneer breakthrough therapies with the potential to set new standards of care, driving positive change in treatment paradigms and improving the lives of patients worldwide." SOURCE Akeso, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准免疫疗法

2025-03-16

·正大天晴

派安普利单抗又一适应症获批！一线治疗鼻咽癌

3月14日，正大天晴派安普利单抗注射液（商标名：安尼可）又一适应症——用于联合化疗一线治疗复发或转移鼻咽癌（NPC）获得国家药监局（NMPA）批准上市，是派安普利单抗获批上市的第4个适应症。派安普利单抗是一款采用IgG1亚型并进行Fc段改造的新型差异化抗PD-1单抗。2023年4月，派安普利单抗在澳大利亚、新西兰、巴布亚新几内亚，以及新加坡、马来西亚等东南亚11个国家的独家销售权被授予给Specialised Therapeutics公司。此前，派安普利单抗已在中国获批3项适应症，分别为联合化疗一线治疗局部晚期或转移鳞状非小细胞肺癌，至少经过二线系统化疗复发或难治性经典型霍奇金淋巴瘤，以及接受过二线及以上系统治疗失败的复发/转移性鼻咽癌。派安普利单抗治疗二线及以上治疗（至少包含一线含铂化疗）失败的转移性鼻咽癌的Ⅱ期研究数据显示，客观缓解率为28.0%，中位无进展生存期为3.6个月，中位总生存期为22.8个月。在一线及既往多线治疗失败的复发或转移鼻咽癌患者中，派安普利单抗均展现出了较好的肿瘤客观缓解率和生存获益，且安全性和耐受性良好，整体免疫相关不良反应发生率低。声明： 1.新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。 2.本公司不对任何药品和/或适应症作推荐。 3.本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。内容来源：医药观澜

临床2期上市批准

2025-03-03

·正大天晴药业集团

月度盘点 | 正大天晴2月要闻回顾

过去的一个月正大天晴发生了哪些新鲜事让我们一起来回顾一下吧 #1 国产首创突破！妥洛特罗贴剂（德瑞妥）获批上市，守护全年龄段呼吸疾病患者健康 2月7日，北京泰德制药研发的妥洛特罗贴剂（商标名：德瑞妥）获得国家药品监督管理局颁发的上市批件，是首个获批上市的国产妥洛特罗贴剂。这款创新贴剂，通过透皮给药系统实现药剂缓释，即可在“晨降”高危时段持续舒张支气管，降低夜间发病风险。正大天晴将携手北京泰德制药保证该产品供应，守护全年龄段呼吸疾病患者健康。（点击此处跳转至原链接） #2 正大天晴国内率先完成等效性研究，乌美溴铵维兰特罗吸入粉雾剂上市申请获受理 2月9日，正大天晴开发的乌美溴铵维兰特罗吸入粉雾剂上市申请获CDE受理，适用于慢性阻塞性肺疾病（COPD）的长期维持治疗，有望为国内超1亿慢阻肺病患者提供新的治疗选择。正大天晴作为国内首家完成双支扩粉雾剂等效性研究的医药企业，此次申报进程的推进将进一步巩固公司在呼吸系统疾病治疗领域的领先地位。（点击此处跳转至原链接） #3 彭博《商业周刊》专访谢其润：只有创新才能在全球医药竞争中立足中国生物制药董事会主席谢其润获选“2024彭博《商业周刊》年度人物50”。2月14日，《商业周刊》发表了题为《中国生物制药董事会主席谢其润：只有创新才能在全球医药竞争中立足》的专访文章。（点击此处跳转至原链接） #4 纳入国家优化创新药临床试验审评试点项目，正大天晴1类新药研发提速 2月11日，正大天晴申报的1类创新药TQB2210临床试验申请获国家药监局药品审评中心（CDE）受理。作为公司首个纳入《优化创新药临床试验审评审批试点工作方案》的试点项目，TQB2210临床试验审评周期将缩短50%以上，从而有望更快惠及肿瘤患者。近年来，企业通过研发投入与政策借力，实现创新药管线的爆发式增长。（点击此处跳转至原链接） #5 安罗替尼“再挑战”研究入选2025 ESMO SRCC小型口头报告盐酸安罗替尼关于晚期软组织肉瘤（STS）的多中心回顾性研究，入选2025年欧洲肿瘤内科学会肉瘤及罕见肿瘤大会（ESMO SRCC）小型口头报告（Mini Oral）。该研究聚焦于安罗替尼“再挑战”既往治疗发生进展STS患者的疗效与安全性，将于3月20日至22日在瑞士卢加诺举行的大会上展示最新研究数据。（点击此处跳转至原链接） #6 南京市委书记周红波会见谢承润：支持打造百亿级链主企业共建生物医药创新发展高地 2月19日，南京市委书记周红波会见中国生物制药首席执行长、正大天晴董事长谢承润一行。（点击此处跳转至原链接） #7 《新华日报》头版头条文章点赞正大天晴 2月20日，《新华日报》头版头条发表文章《其命维新，稳步走好“第一方阵”》，对2024年江苏因地制宜发展新质生产力，“创新江苏”多项指标全国居首，进行了深度报道。其中，正大天晴聚焦国际前沿靶点，在肿瘤、肝病、呼吸等重点治疗领域创新药物研发成果斐然受到关注。（点击此处跳转至原链接） #8 当选上海生物医药商会副会长谢承润:以“创新”“国际化”为战略双翼构建全球化产业协同体系 2月22日，上海市工商联生物医药商会第一届一次会员会议暨生物医药发展大会举行。上海市副市长刘多、陈宇剑，市政协副主席、市工商联主席寿子琪，中国药学会理事长孙咸泽出席。当选副会长的中国生物制药首席执行长、正大天晴董事长谢承润受邀参加“创新与出海”圆桌会，表示将以“数字化赋能”与“生态链协同”推动创新突破与国际化布局，与行业伙伴携手推动中国医药从“跟随”到“引领”的跨越。（点击此处跳转至原链接） #9 正大天晴“靶免联合”新突破，肺巨细胞癌患者无进展生存期达30个月 1类创新药安罗替尼联合派安普利单抗治疗晚期肺巨细胞癌的罕见病例报道，在医学期刊《Frontiers in Oncology》上发表，成功帮助一名晚期肺巨细胞癌伴脑转移、PD-L1高表达和TP53突变患者实现无进展生存30个月，为罕见肺癌治疗提供了新的思路和希望。（点击此处跳转至原链接） #10 “天韵”破局！新研究为血液病合并脓毒症治疗提供关键证据当地时间2月23日至25日，一项关于多黏菌素E甲磺酸钠（商标名：天韵）治疗血液病合并脓毒症的研究在美国重症医学会年会（SCCM 2025）以口头报告的形式公布，为破解这一困局提供了关键证据。（点击此处跳转至原链接） #11 关注罕见病，让生命不因“罕见”而孤独全球3.5亿罕见病患者中，中国有近2000万患者在与命运抗争。正大天晴2款在研的重磅产品正致力于攻克《罕见病目录》中的治疗难题。《罕见病目录》之外，正大天晴还有4款1类新药，正在向发病率极低的国际罕见病种发起挑战。（点击此处跳转至原链接）注：以上内容根据本公众号发稿时间统计。声明：本文的著作权由原作者或本公司享有，未经授权，不得以转载、复制、摄制、改编、汇编等方式使用。文中出现的人物肖像，其肖像权归本人所有，未经授权，禁止使用。 ● 月度盘点 | 正大天晴12月要闻回顾 ● 月度盘点 | 正大天晴11月要闻回顾 ● 月度盘点 | 正大天晴10月要闻回顾

上市批准申请上市

100 项与派安普利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	派安普利单抗	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
鼻咽癌	中国	正大天晴康方(上海)生物医药科技有限公司	2024-04-24
鳞状非小细胞肺癌	中国	正大天晴康方(上海)生物医药科技有限公司	2023-01-10
典型霍奇金淋巴瘤	中国	中山康方生物医药有限公司	2021-08-03
典型霍奇金淋巴瘤	中国	正大天晴药业集团股份有限公司	2021-08-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝细胞癌	申请上市	中国	正大天晴药业集团南京顺欣制药有限公司	2024-11-21
肝细胞癌	申请上市	中国	中山康方生物医药有限公司	2024-11-21
复发性鼻咽癌	临床3期	中国	中山康方生物医药有限公司	2021-08-16
鼻咽癌	临床3期	加拿大	中山康方生物医药有限公司	2021-08-16
晚期肝细胞癌	临床3期	中国	正大天晴药业集团股份有限公司	2020-08-11
转移性非小细胞肺癌	临床3期	中国	中山康方生物医药有限公司	2018-11-27
转移性非鳞状非小细胞肺癌	临床3期	中国	中山康方生物医药有限公司	2018-11-12
腺癌	药物发现	中国	正大天晴药业集团股份有限公司	2020-05-20
进展期胃腺癌	药物发现	中国	正大天晴药业集团股份有限公司	2020-05-20
鳞状细胞肺癌	药物发现	中国	中山康方生物医药有限公司	2018-12-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04846634 (ALTER-L043, ESMO_IO2024) 人工标引	临床2期	局部晚期非小细胞肺癌辅助 \| 新辅助	90	Penpulimab + Chemotherapy + Anlotinib	(廠糧製構築齋艱壓構衊) = 廠醖鏇艱廠餘範窪淵鹽夢鹹艱鏇憲糧構餘蓋廠 (鹽範願積膚憲廠顧鬱簾 ) 更多	积极	2024-12-12
				Penpulimab + Chemotherapy	(廠糧製構築齋艱壓構衊) = 窪淵遞築鏇範壓憲鬱廠夢鹹艱鏇憲糧構餘蓋廠 (鹽範願積膚憲廠顧鬱簾 ) 更多
NCT05563480 (ESMO_IO2024) 人工标引	临床2期	鼻咽癌	17	TQB2618 + Penpulimab	(淵鑰製範艱淵憲壓觸選) = 壓鑰餘齋壓選遞壓窪醖淵鹽襯糧窪製鹹鑰顧蓋 (淵襯襯醖糧餘範築積夢 ) 更多	不佳	2024-12-12
NCT05894421 (ASH2024) 人工标引	临床1期	霍奇金淋巴瘤 \| 纵隔大b细胞淋巴瘤 \| 弥漫性大B细胞淋巴瘤 \| 淋巴瘤	21	TQB2223 + Penpulimab	(廠構範願齋簾衊鬱餘鑰) = 遞遞積鑰夢膚窪顧廠鹹選廠鏇鏇蓋製糧遞鏇衊 (鬱艱獵繭衊製選鑰壓襯 ) 更多	积极	2024-12-08
				TQB2223 + Penpulimab (HL patients previously treated with anti-PD-1/L1)	(廠構範願齋簾衊鬱餘鑰) = 鹽構窪糧網獵襯衊廠製選廠鏇鏇蓋製糧遞鏇衊 (鬱艱獵繭衊製選鑰壓襯 ) 更多
ALTER-UC-007 (NEWS) 人工标引	临床2期	膀胱癌	6	吉西他滨+顺铂 or 派安普利单+安罗替尼	(齋鏇醖衊夢製選繭鹽廠) = 壓選顧鏇築獵積構廠糧觸遞餘鏇鏇廠鑰糧襯壓 (鏇襯鬱網鹽襯衊壓簾鏇 )	积极	2024-10-30
				吉西他滨+顺铂 or 派安普利单+安罗替尼 (受手术的患者)	(簾鹽窪選鹽觸艱範齋醖) = 獵獵淵壓廠糧鑰餘鏇構淵醖廠網網糧積齋遞網 (獵鬱餘範夢艱餘蓋夢鹽 )
NCT04203719 (Pubmed) 人工标引	临床2期	小细胞肺癌二线	21	Anlotinib 10/12 mg QD + Penpulimab 200 mg IV	(積餘獵餘範觸構觸廠選) = 網膚積鑰憲廠蓋壓積繭選蓋選夢網鏇膚鹹獵鹹 (鏇構襯獵艱網遞積網窪, 17.7 ~ 66.6) 更多	积极	2024-10-01
NCT05244993 (ESMO2024) 人工标引	临床2期	晚期三阴性乳腺癌一线	33	AK105, anlotinib, nab-P	(選範蓋網網襯齋構蓋觸) = 構襯鹽願鏇醖夢鹹淵鹹餘鹹繭襯齋鹹醖選願夢 (壓構獵獵網構選簾繭壓, 60.65 ~ 93.45) 更多	积极	2024-09-16
ChiCTR2200062189 (keynote-564, ESMO2024) 人工标引	临床2期	肾细胞癌辅助	63	Penpulimab 200 mg	(鹹衊獵壓糧簾衊繭憲衊) = 鹹鹽製窪鬱繭艱淵繭鑰範鹹鹽窪製蓋醖窪齋糧 (選衊鹹醖糧窪膚鑰壓遞 ) 更多	积极	2024-09-15
				penpulimab (Observation)	(鹹衊獵壓糧簾衊繭憲衊) = 壓鹹淵憲襯廠鏇襯遞膚範鹹鹽窪製蓋醖窪齋糧 (選衊鹹醖糧窪膚鑰壓遞 ) 更多
NCT04344158 (ALTN-AK105-III-02, ESMO2024 \| PRNewswire) 人工标引	临床3期	晚期肝细胞癌一线	649	Anlotinib + Penpulimab	(廠選鹹鬱觸壓鑰積壓襯) = 鏇築廠簾蓋觸齋觸醖簾範壓願願築廠壓壓餘願 (壓鏇積膚選衊衊獵糧壓 ) 更多	积极	2024-09-13
				Sorafenib	(廠選鹹鬱觸壓鑰積壓襯) = 窪願餘網構餘鹹醖衊顧範壓願願築廠壓壓餘願 (壓鏇積膚選衊衊獵糧壓 ) 更多
WCLC2024 人工标引	临床1期	非小细胞肺癌	93	TQB2618 12Penpulimab	(鏇遞積夢範願餘築糧鑰) = 網艱遞衊衊網鹹餘醖構淵顧膚餘網壓簾衊襯選 (艱蓋鹽膚鏇鏇顧網製觸 ) 更多	积极	2024-09-10
				TQB2618 15penpulimab	(鏇遞積夢範願餘築糧鑰) = 顧鑰壓夢築淵網鏇願鹽淵顧膚餘網壓簾衊襯選 (艱蓋鹽膚鏇鏇顧網製觸 ) 更多
NCT05460481 (WCLC2024) 人工标引	临床2期	晚期非小细胞肺癌二线 driver gene-negative	13	Anlotinibpenpulimab	(襯選壓範網獵襯鬱齋簾) = 築壓築憲廠網遞積夢憲襯齋齋網餘簾艱築願構 (醖獵願餘網積範憲夢廠 ) 更多	积极	2024-09-09